Positive News SentimentPositive NewsNASDAQ:HRTX Heron Therapeutics (HRTX) Stock Forecast, Price & News $1.19 -0.09 (-7.03%) (As of 05/30/2023 ET) Add Compare Share Share Today's Range$1.15▼$1.3150-Day Range$1.19▼$2.8852-Week Range$1.07▼$5.62Volume2.89 million shsAverage Volume2.20 million shsMarket Capitalization$142.45 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Heron Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside530.3% Upside$7.50 Price TargetShort InterestBearish18.09% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.90) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector576th out of 1,009 stocksPharmaceutical Preparations Industry280th out of 494 stocks 3.5 Analyst's Opinion Consensus RatingHeron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Heron Therapeutics has a forecasted upside of 530.3% from its current price of $1.19.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted18.09% of the outstanding shares of Heron Therapeutics have been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Heron Therapeutics has recently decreased by 2.91%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHeron Therapeutics has received a 61.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Antiemetics and antinauseants (A04)", "Bupivacaine", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Heron Therapeutics is -1.96. Previous Next 2.8 News and Social Media Coverage News SentimentHeron Therapeutics has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Heron Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for HRTX on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat Follows11 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.02% of the stock of Heron Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($0.90) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeron Therapeutics has a P/B Ratio of 10.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Heron Therapeutics (NASDAQ:HRTX) StockHeron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.Read More Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTX Stock News HeadlinesMay 22, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Heron Therapeutics (NASDAQ:HRTX)May 12, 2023 | msn.comDisastrous Earnings Report Takes Down Heron TherapeuticsMay 30, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 12, 2023 | markets.businessinsider.comHeron Therapeutics (HRTX) Gets a Buy from NeedhamMay 12, 2023 | msn.comNeedham Maintains Heron Therapeutics (HRTX) Buy RecommendationMay 12, 2023 | msn.comHeron stock slumps ~35% amid quarterly misses on both linesMay 12, 2023 | markets.businessinsider.comAnalyst Expectations for Heron Therapeutics's FutureMay 11, 2023 | msn.comRecap: Heron Therapeutics Q1 EarningsMay 30, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 10, 2023 | msn.comEarnings Preview: Heron TherapeuticsMay 6, 2023 | marketwatch.comHeron Therapeutics Inc. Commo $HRTX Trading ReportMay 5, 2023 | finance.yahoo.comInvestors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) TunnelApril 24, 2023 | americanbankingnews.comNeedham & Company LLC Reaffirms "Buy" Rating for Heron Therapeutics (NASDAQ:HRTX)April 24, 2023 | americanbankingnews.comHeron Therapeutics (NASDAQ:HRTX) Rating Reiterated by Needham & Company LLCApril 24, 2023 | americanbankingnews.comHeron Therapeutics (NASDAQ:HRTX) Given Buy Rating at Needham & Company LLCApril 21, 2023 | msn.comNeedham Reiterates Heron Therapeutics (HRTX) Buy RecommendationApril 20, 2023 | finance.yahoo.comHeron Therapeutics Announces Commercial Leadership ChangesApril 17, 2023 | finance.yahoo.comHeron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare ConferenceApril 6, 2023 | finance.yahoo.comWhy Shares of Heron Therapeutics Jumped ThursdayApril 6, 2023 | finance.yahoo.comWhy Heron Therapeutics Stock Has Been on Fire This WeekApril 3, 2023 | msn.comHeron Therapeutics Separates Chairman & CEO Roles; Barry Quart DepartsApril 3, 2023 | marketwatch.comHeron Therapeutics Chairman, CEO Barry Quart Resigns >HRTXApril 3, 2023 | finance.yahoo.comHeron Therapeutics Announces New CEO and Board ChairmanApril 2, 2023 | americanbankingnews.comFY2023 EPS Estimates for Heron Therapeutics, Inc. Boosted by Analyst (NASDAQ:HRTX)March 27, 2023 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2022 Earnings Call TranscriptMarch 27, 2023 | americanbankingnews.comEvercore ISI Cuts Heron Therapeutics (NASDAQ:HRTX) Price Target to $10.00March 25, 2023 | americanbankingnews.comNeedham & Company LLC Lowers Heron Therapeutics (NASDAQ:HRTX) Price Target to $7.00See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTX Company Calendar Last Earnings3/23/2023Today5/30/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HRTX CUSIPN/A CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees302Year Founded1983Price Target and Rating Average Stock Price Forecast$7.50 High Stock Price Forecast$10.00 Low Stock Price Forecast$5.50 Forecasted Upside/Downside+541.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-182,020,000.00 Net Margins-132.57% Pretax Margin-132.57% Return on Equity-21,127.62% Return on Assets-61.11% Debt Debt-to-Equity Ratio11.00 Current Ratio2.29 Quick Ratio1.62 Sales & Book Value Annual Sales$107.67 million Price / Sales1.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book10.64Miscellaneous Outstanding Shares119,710,000Free Float113,705,000Market Cap$140.06 million OptionableOptionable Beta0.91 Social Links Key ExecutivesCraig A. CollardChief Executive Officer & DirectorDavid L. SzekeresChief Operating Officer & Executive Vice PresidentThomas B. OttoboniChief Scientific Officer & SVP-PharmaceuticalChris M. StorgardChief Medical OfficerLisa PerazaChief Accounting Officer & Vice PresidentKey CompetitorsCorvus PharmaceuticalsNASDAQ:CRVSLarimar TherapeuticsNASDAQ:LRMRPuma BiotechnologyNASDAQ:PBYIOrganigramNASDAQ:OGILumiraDxNASDAQ:LMDXView All CompetitorsInstitutional OwnershipAmeriprise Financial Inc.Bought 100,133 shares on 5/22/2023Ownership: 0.295%JPMorgan Chase & Co.Bought 332,792 shares on 5/18/2023Ownership: 5.920%New York State Common Retirement FundSold 27,926 shares on 5/18/2023Ownership: 0.895%Geode Capital Management LLCBought 16,512 shares on 5/16/2023Ownership: 1.656%Susquehanna Fundamental Investments LLCSold 9,365 shares on 5/16/2023Ownership: 0.210%View All Institutional Transactions HRTX Stock - Frequently Asked Questions Should I buy or sell Heron Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HRTX shares. View HRTX analyst ratings or view top-rated stocks. What is Heron Therapeutics' stock price forecast for 2023? 2 Wall Street research analysts have issued 12 month price objectives for Heron Therapeutics' stock. Their HRTX share price forecasts range from $5.50 to $10.00. On average, they predict the company's share price to reach $7.50 in the next year. This suggests a possible upside of 541.0% from the stock's current price. View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts. How have HRTX shares performed in 2023? Heron Therapeutics' stock was trading at $2.50 at the start of the year. Since then, HRTX stock has decreased by 53.2% and is now trading at $1.17. View the best growth stocks for 2023 here. When is Heron Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our HRTX earnings forecast. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) released its earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08. The biotechnology company earned $30 million during the quarter, compared to analysts' expectations of $27.24 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 21,127.62% and a negative net margin of 132.57%. The company's quarterly revenue was up 44.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.54) EPS. What ETFs hold Heron Therapeutics' stock? ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD), Simplify Propel Opportunities ETF (SURI) and Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN). What is Heron Therapeutics' stock symbol? Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX." Who are Heron Therapeutics' major shareholders? Heron Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.88%), JPMorgan Chase & Co. (5.92%), Great Point Partners LLC (4.88%), Palisade Capital Management LP (3.33%), ArrowMark Colorado Holdings LLC (2.80%) and State Street Corp (2.14%). Insiders that own company stock include Craig A Johnson, David Leslie Szekeres, Kimberly Manhard and Waage Christian. View institutional ownership trends. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Heron Therapeutics' stock price today? One share of HRTX stock can currently be purchased for approximately $1.17. How much money does Heron Therapeutics make? Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $140.06 million and generates $107.67 million in revenue each year. The biotechnology company earns $-182,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. How many employees does Heron Therapeutics have? The company employs 302 workers across the globe. Does Heron Therapeutics have any subsidiaries? The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..Read More How can I contact Heron Therapeutics? Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.herontx.com. The biotechnology company can be reached via phone at (858) 251-4400, via email at ir@herontx.com, or via fax at 650-365-6490. This page (NASDAQ:HRTX) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.